On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug, Relyvrio, after a large clinical trial showed that the medicine, approved by the Food and Drug Administration in 2022, was not effective.
Amylyx’s co-CEOs, Joshua Cohen and Justin Klee, had previously publicly promised that they would withdraw the drug if further testing failed to show a benefit. After they made good on that promise, STAT senior writers Adam Feuerstein and Matthew Herper talked through what to make of it all.
Matt: I have to say I’m impressed. Amylyx had seemed to telegraph that it would actually follow through with withdrawing the drug when the negative data were released. But I half expected that it would still find a loophole or a way to drag things out.
Click this link for the original source of this article.
Author: Adam Feuerstein and Matthew Herper
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.